Alongside the data in PsA, UCB will present at EULAR new results demonstrating that Bimzelx delivered sustained clinical ...

Discover why nails separate from the nail bed, what causes onycholysis, and how to treat this common but concerning nail ...

Most people affected by psoriasis don’t pay much attention to the changes in their skin to begin with. But when the patches ...

An analysis of key drug trials for psoriatic arthritis shows geographic disparities and racial gaps; most participants have ...

Enthesitis is a key, but often overlooked, feature of psoriatic arthritis. Learn how this inflammation at tendon and ligament attachment sites can affect diagnosis, symptoms, and treatment.

European researchers unveil digital tools and explainable AI that personalize psoriatic arthritis care, enabling early ...

Late-breaking data reveal durable improvements in joint, skin, and quality of life outcomes with deucravacitinib.

Two studies suggest there is no significant benefit of early biologics over standard step-up care with methotrexate, but ...

Patients with uveitis had a higher risk for psoriatic arthritis and psoriasis, whereas those with psoriatic arthritis had a higher risk for uveitis.

EULAR - The European Alliance of Associations for Rheumatology - recommends a treat-to-target approach, and suggests more ...

Clinical improvements were achieved and maintained for up to 3 years among bDMARD-naïve patients with PsA who received bimekizumab.

When Dawn Steiner awoke one morning with joint pain so severe she couldn't even lift her arms, she knew something was wrong.